In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ...

A 1960s housing estate in Coventry is being demolished after structural issues were found in the blocks. Work to bulldoze the ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

National Highways has issued a warning to drivers in the Midlands as slip road closures will be in place on the M42 ...

A 21,000-square-foot commercial center recently sold for $9.22 million, according to public records. Coventry Crossing, ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Listen to the full interview with Frank Lampard on the Sky Sports One on One podcast; watch Luton vs Coventry live on Sky ...